An Assessment Of The Efficacy Of Pidotimod In The Adjuvant Treatment Of Children With Asthma

Objective: The aim of this research was to assess the effectiveness of pidotimod in treating pediatric asthma.Additionally,to assess the enhancement of lung function,nitric oxide and EOS exhaled before and after the treatment,as well as to present a novel adjuvant approach for children with asthma.Methods: A total of 80 children aged 6-14 years with acute asthma attack(mild to moderate)diagnosed and treated in the pediatric outpatient department of the Affiliated Hospital of Yan ’an University from January 2021 to November 2022 were selected as the study objects.By random sampling method,80 children aged 6-14 years with acute asthma attack(mild to moderate)were divided into control group and observation group,40 cases in the control group and 40 cases in the observation group.The control group was given Astra Zeneca AB(imported drug registration No.: H20080249,specification:80ug:4.5ug*60 inhale *1)2 times/day.Observation group was additionally given pidotimod granule(Zhejiang Xianzhu Pharmaceutical,National Medicine No.H20030324,specification: 2g: 0.4g,6 bags/box)on the basis of conventional treatment.Acute phase: 1pack/time(given before breakfast),2 times a day,for 2 consecutive weeks,two weeks later changed to prophylactic drug,1 pack/time,once a day,for 30 consecutive days.The changes of pulmonary function,exhaled nitric oxide and eosinophils were observed before treatment and 14 days,1 month and 3 months after treatment.The changes of immunoglobulin indexes before treatment and 1 month and 3 months after treatment were observed.At the same time,the relevant indicators of asthma control of the two groups of children with asthma were collected before treatment and 1 month after treatment(whether they had daytime asthma symptoms > 2 times/week,the number of times they woke up due to asthma at night,the number of times they used SABA,and whether they had limited activity).The number of asthma attacks before treatment and the number of asthma attacks within 6 months after treatment were collected.Results: 1.There was no significant difference in immunoglobulin between the two groups before treatment(P>0.05).There were significant differences in Ig A,Ig G,Ig M and Ig E at 1 and 3 months after treatment(P < 0.05).After 1 month and 3 months of treatment,Ig A,Ig G and Ig M in the observation group were higher than those in the control group,while Ig E was lower in the observation group.2.No noteworthy disparity in pulmonary function indices was seen between the two groups before the treatment(P>0.05).Nevertheless,after 1 and 3 months of treatment,the lung function of both groups was significantly enhanced(P<0.05),with the observation group’s enhancement being more pronounced than that of the control group.3.No noteworthy difference in the nitric oxide exhaled between the two groups was seen before treatment(P>0.05).However,after 1,3 months of therapy,the airway of the observation group had a notably decreased amount of FENO 50,FENO 200,and Ca NO(P<0.05)than the control group.4.No noteworthy disparity in EOS was observed between the two groups prior to treatment(P>0.05).At 1 and 3 months post-treatment,the EOS value in the observation group was significantly lower than that of the control group,a divergence that was statistically significant(P<0.05).5.No significant difference in asthma control between the two groups was noticed before treatment(P>0.05).However,after 1 month of therapy,the control level of asthma in the 2 groups was significantly higher than the control group(P<0.05),and this difference was statistically significant.6.No noteworthy distinction was seen in the amount of asthma episodes between the two groups prior to medication(P>0.05),and the observation group’s asthma attacks were notably lower than those of the control group within 6 months of medication(P<0.05),and this disparity was significant.Conclusions: 1.Taking pidotimod for more than 1 month can significantly improve immune function,airway inflammation,and asthma symptoms in children with asthma.2.The addition of pidotimod,with its high safety factor and its ability to significantly reduce airway inflammation,improve immunity,and be applied in clinical practice,is a immunotherapy for children with asthma.